Chemo before stomach surgery with different cycles
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial studies whether giving oxaliplatin plus S-1 (SOX) chemotherapy before stomach surgery works best when given for different cycle lengths. It may help shrink stage III gastric cancer before a standard D2 gastrectomy and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 70 years old and able to move around (not bedridden).
- You have stage III stomach cancer confirmed by scans and a look inside the abdomen if needed.
- Your performance status is ECOG 0 to 1 (you are fully active or limited only in strenuous activity).
- Your blood counts and organ tests are strong enough (hemoglobin, white cells, platelets, liver, kidneys, and albumin).
- Your heart tests are acceptable (left-heart pumping strength at least 50% and no major uncontrolled heart problems).
- You have never had chemo, radiation, or immunotherapy before for this cancer, and you can sign consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of four chemotherapy drugs (irinotecan liposome, 5-FU + leucovorin, oxaliplatin, and Karelizumab) given before surgery to shrink stomach cancer. The goal is to see if this combination makes the cancer easier to remove and improves outcomes.
This trial tests a combination of chemotherapy drugs given before surgery for locally advanced stomach or gastroesophageal junction cancer. It aims to see if this approach helps shrink the tumor and improve outcomes.
This trial tests whether giving oxaliplatin for a shorter or longer time works best after curative surgery for stage II–III stomach (or stomach–esophagus junction) cancer. It aims to improve outcomes while balancing side effects from chemotherapy.
This trial tests combining chemotherapy (SOX), an immunotherapy drug (tislelizumab), and low-dose radiation before surgery for people with locally advanced stomach or gastroesophageal junction cancer. The goal is to see if this combination shrinks tumors more effectively.
This trial is testing a combination of three medicines—an immunotherapy (anti-PD-1), an immune booster (thymalfasin), and a chemotherapy regimen (SOX)—given before surgery to shrink stage III stomach or gastroesophageal junction cancer and improve outcomes.
This Phase 2 trial tests whether adding nivolumab to standard chemotherapy (SOX) given before and around surgery can improve outcomes for people with certain stomach or stomach–esophagus junction cancers. It aims to shrink or control the cancer and make surgery more effective.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.